Cellmid 2018 Annual Report 13
Mr Bruce Gordon Director (Non-executive)
Qualifications BA, Macquarie University, Fellow of The Institute of Chartered Accountants Australia and New
Zealand, Fellow of The Australian Institute of Company Directors
Experience An audit and corporate finance specialist, and an experienced finance professional with a
career spanning more than 35 years advising and providing financial services to private and
publicly listed companies as well as subsidiaries of large multinationals.
Interest in shares and options Shares: 101,316 indirectly held
Options: 100,000 (Expiry: 19 November 2018, exercisable at $1.20 each) indirectly held
Special responsibilities Chairman of the Audit and Risk Committee and member of the Nomination and Remuneration
Committee
Other directorships in listed None
entities held in the previous
three years
Dr Fintan Walton Director (Non-executive)
Qualifications PhD, Genetics, Trinity College Dublin
Experience Founder and CEO of PharmaVentures Ltd, a UK based corporate advisory firm that provides
advice on all aspects of corporate transactions, business brokering, mergers and acquisitions
and licensing deals to a diversified global network.
Interest in shares and options Shares: 12,500 directly held
Shares: 52,500 indirectly held
Options: 100,000 (Expiry: 19 November 2018, exercisable at $1.20 each) directly held
Special responsibilities Member of the Audit and Risk Committee^ and member of the Nomination and Remuneration
Committee
^ Dr Fintan Walton resigned from the Audit and Risk Committee on 21 February 2018
Other directorships in listed None
entities held in the previous
three years